Evidence map›Paper›PMID 41555001›Full record

ArticleNPJ precision oncology2026

Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkers.

R Trozzi, M Salvi, M Karimi, A Minucci, G Raspaglio, M De Donato, M Buttarelli, A Piermattei, L Vaccaro, A Grimaldi and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

R Trozzi *Department of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
M Salvi *Telethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
M KarimiBioinformatics Research Core Facility, Gemelli Science and Technology Park (GSTeP), Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
A MinucciDepartmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
G RaspaglioDepartmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
M De DonatoDepartmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
M ButtarelliUniversity Department of Life Sciences and Public Health, Section of Gynecology and Obstetrics, Catholic University of the Sacred Heart, Rome, Italy.
A PiermatteiDepartment of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
L VaccaroTelethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
A GrimaldiTelethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
R De SantisTelethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
M MassaTelethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
F SillanoDepartment of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
L GiacòBioinformatics Research Core Facility, Gemelli Science and Technology Park (GSTeP), Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
L MastrantoniCatholic University of the Sacred Heart, Rome, Italy.
V IacobelliDepartment of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
F CamardaDepartment of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
M CesanaTelethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
S DurantiScientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
M C SassuDepartment of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
P MattognoDepartment of Neuroscience, Sensory Organs and Chest, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
A FagottiDepartment of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. anna.fagotti@policlinicogemelli.it.
C MarchettiDepartment of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
G ScambiaDepartment of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
C NeroDepartment of Women's, Children's and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
D CacchiarelliTelethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy. d.cacchiarelli@tigem.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) remains the most lethal gynaecological malignancy in developed countries, with recurrence and drug resistance posing significant clinical challenges. Brain metastases (BM) from epithelial ovarian cancer, once rare, are an increasing phenomenon and are characterised by a dismal prognosis. To explore the molecular underpinnings of BM in EOC, we conducted a multimodal genomics and transcriptomics analysis of matched primary tumour and brain metastases samples from a retrospective cohort. Our findings revealed high genomic concordance between primary tumour (PT) and BM, with alterations in key pathways such as MYC (MYC Proto-Oncogene, bHLH Transcription Factor) targets, extracellular matrix remodelling, and inflammatory signalling characterizing the BM. AFP (Alpha-fetoprotein) and GFAP (Glial Fibrillary Acidic Protein) emerged as potential biomarkers from the primary lesion for BM onset, while network analysis identified MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), GDF15 (Growth Differentiation Factor 15), and S100A9 (S100 Calcium Binding Protein A9) as candidate mediators of tumour-brain crosstalk. These results offer new insights into EOC brain tropism, highlighting potential targets for therapeutic intervention and personalized patient management in the precision oncology era.

Identifiers

PMID41555001
PMCPMC12948965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.